kineret
swedish orphan biovitrum ab (publ) - anakinra - arthritis, rheumatoid; covid-19 virus infection - inmunosupresores - la artritis reumatoide (ar)kineret está indicado en adultos para el tratamiento de los signos y síntomas de la ar en combinación con metotrexato, con una respuesta inadecuada a metotrexato solo. covid-19kineret is indicated for the treatment of coronavirus disease 2019 (covid-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (supar) ≥ 6 ng/ml. periodic fever syndromeskineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:cryopyrin-associated periodic syndromes (caps)kineret is indicated for the treatment of caps, including:neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca)muckle-wells syndrome (mws)familial cold autoinflammatory syndrome (fcas)familial mediterranean fever (fmf)kineret is indicated for the treatment of familial mediterranean fever (fmf). kineret debe administrarse en combinación con colchicina, si es apropiado. still’s diseasekineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of still’s disease, including systemic juvenile idiopathic arthritis (sjia) and adult-onset still’s disease (aosd), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (nsaids) or glucocorticoids. kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (dmards).
uroquinasa syner medica 100.000 u.i. polvo para solucion inyectable y para perfusion
syner-medica b.v. - uroquinasa - polvo para soluciÓn inyectable y para perfusiÓn - 100.000 ui - uroquinasa 100000 ui - uroquinasa
uroquinasa syner medica 250.000 u.i. polvo para solucion inyectable y para perfusion
syner-medica b.v. - uroquinasa - polvo para soluciÓn inyectable y para perfusiÓn - 250.000 ui - uroquinasa 250000 ui - uroquinasa
uroquinasa syner medica 500.000 u.i. polvo para solucion inyectable y para perfusion
syner-medica b.v. - uroquinasa - polvo para soluciÓn inyectable y para perfusiÓn - 500.000 ui - uroquinasa 500000 ui - uroquinasa
amadaz 50mg/10ml solucion inyectable y para perfusion
accord healthcare s.a.c. - solucion inyectable y para perfusion - por ampolla - midazolam
amadaz 5 mg/5 ml solucion inyectable y para perfusion
accord healthcare s.a.c. - solucion inyectable y para perfusion - por ampolla - midazolam
heparina sodica solución inyectable 25000 ui/ 5 ml
inversiones asia s.p.a. - heparina - sin formulas
bismatrol
major pharmaceuticals, livonia, estados unidos de américa. - subsalicilato de bismuto - tableta masticable - 262,0 mg
bismatrol®
major pharmaceuticals. - subsalicilato de bismuto (total de salicilato 102 mg) - tableta masticable - 262 mg